Track records, product handling limitations, and cost are all factors to consider when outsourcing parenteral manufacturing. Choosing the right CDMO partner is not an easy task, but Curia has resources to make the decision easier. To learn more, Pharmaceutical Technology sat down with Dr. Ronald Aungst [Vice President, Portfolio and Sourcing for Drug Product, Curia] to discuss what CDMOs have to offer and how these partnerships can improve tech transfers and drug product development.
Ready to move from idea to impact?
Whether you have a question for our team or an opportunity you’re eager to pursue, one of our experts can help you get started.Contact Us
More from Curia
Lyophilization: Protecting and preserving biologics
Lyophilization, also known as freeze-drying, is often a crucial step in the manufacturing process of biologics drug products. Biologics are large, complex molecules used to treat various diseases, including cancer, autoimmune disorders, and rare gene...
Rapid discovery and characterization of monoclonal antibodies against the SARS-CoV-2 Delta spike protein
In the fall of 2021, the Delta variant of SARS-CoV-2 was the dominant strain in the US, being both more contagious than previous variants and more likely to lead to “long COVID” than subsequent Omicron variants. Here we describe the discovery and...